The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
PHASE2
Colorectal cancer is a malignant tumor ranking among the top four in incide...
Status
Recruiting
Location
Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang Province 310999
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
PHASE1
This study aims to evaluate the efficacy and safety of the concurrent combi...